In: プレスリリース

Jonathan Santomauro recognized for dedication to his company and community in the Philadelphia Business Journal’s annual list of dynamic up-and-comers.

HORSHAM, PA. — April 17, 2018. Global Clinical and Ancillary Supply Chain leader Ancillare, LP, the only organization exclusively serving the end-to-end clinical and ancillary supply chain management needs of large- and middle-market pharmaceutical, biotechnology, and medical device companies, as well as contract and medical research organizations, is pleased to announce Jonathan Santomauro, its President and Co-Founder, has been recognized by the Philadelphia Business Journal as a ‘40 Under 40’ honoree for 2018.

The ‘40 Under 40’ recognizes current and future leaders in the Philadelphia region for their professional excellence, outstanding success, and contributions to their community. Santomauro was selected from more than 400 nominations.

Santomauro was instrumental in defining a singular focus on the clinical and ancillary supply chain industry, and most notably recognized as the driving force behind the Ancillare Turn-Key Operation (A-TKO™) end-to-end solution, which has revolutionized how the industry approaches its clinical supply chain. Through this and other business models, Ancillare will continue to remain at the forefront of the global clinical supply chain industry and will continue to have a direct impact on clinical trial operations, timelines, site performance, and ultimately patient experiences.

Ancillare has grown from a start-up organization to a global organization with over 200 employees around the world. Today, eight of the ten top global pharmaceutical companies, three of the five top global biotechnology companies, and the top two clinical research organizations turn to Ancillare to manage their Phase I-IV trial clinical and ancillary supply demands.

“To be named one of the Philadelphia Business Journal’s ‘40 Under 40’ is such an honor,” said Santomauro. “I am fortunate to have a career that has direct impact on clinical trial operations and the development of innovative therapies for patients around the world.”

Active in the local business community as a member of YPO (formerly Young Presidents Organization) Philadelphia Chapter, and a long-time member of the Advisory Council for Entrepreneurship at Cornell University, where Santomauro obtained his Masters of Business Administration and Bachelor of Arts.

Santomauro will be honored at an award ceremony at SugarHouse Casino in Philadelphia on Thursday, May 10.

About Ancillare, LP

Ancillare is the only organization of its kind with an exclusive focus on the global clinical and ancillary supply chain. Ancillare arms sponsors of global clinical trials with a customized, end-to-end Ancillare Supply Plan, enabling developers of new therapies to optimize their clinical study supply chains using streamlined processes, extensive global buying power, a vast depot network and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s Turn-Key Operations (A-TKO™) model embraces the complexities and globalization of the clinical and ancillary supply chain by reducing both the overall cost and cycle time of clinical trials, and greatly improving operational efficiency across all levels of the value chain.

Ancillare has supported more than 1,500 clinical trials across 80,000 clinical sites over 100 countries with master depots in United States, United Kingdom, and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan, and Ukraine. To learn more, visit Ancillare.com.

 

Approaching Brexit deadline, new licensure will enable continuous global clinical trial operations for sponsors and CROs

HORSHAM, PA. — January 31, 2018. Global Clinical and Ancillary Supply Chain leader Ancillare, LP, the only organization exclusively serving the end-to-end clinical and ancillary supply chain management needs of large- and middle-market pharmaceutical, biotechnology, and medical device companies, as well as contract and medical research organizations, today announced it has been awarded a Wholesale Distribution Authorization (WDA) for Human use by the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA).

The award, which comes in response to the United Kingdom’s anticipated departure from the E.U.—commonly called “Brexit”—will allow Ancillare to continue to support study sponsors’ European needs, even while Brexit’s impact on pharmaceutical supply chains remains unclear. The licensure is a critical victory for the dozens of study sponsors, CROs and MROs for whom the U.K. market is a vital link in complex, global clinical trial portfolios and supply chains.

“I think [the license is] a testament to the integrity and dedication of our global team,” said Joanne Santomauro, CEO, Ancillare. “No matter how rapidly or exponentially things have changed on the global stage, we’ll always be ready to respond in service to our sponsors.”

Ancillare received the license following an intensive evaluation, auditing and inspections process. Among the qualifying criteria for the license was that Ancillare was in full compliance with the 2012 Human Medicines Regulations, and with the requirements of Good Distribution Practice (GDP). Ancillare’s WDA will enable ongoing wholesaling and distribution activities—including procurement, holding, supply and export—from its European regional office and master depot in Milton Keynes.

“I’m proud that Ancillare has emerged even better equipped to meet the clinical and ancillary supply chain needs of study sponsors,” Santomauro added.

In response to its confirmed regulatory compliance status, as well as ongoing Brexit requirements, Ancillare anticipates adding staff at its United Kingdom office, in order to drive global expansion efforts throughout Europe, the Middle East, Africa and Asia-Pacific. Ancillare expects to announce the staff changes later in Q1 2018.

 

About Ancillare, LP

Ancillare is the only organization of its kind with an exclusive focus on the global clinical and ancillary supply chain. Ancillare arms sponsors of global clinical trials with a customized, end-to-end Ancillare Supply Plan, enabling developers of new therapies to optimize their clinical study supply chains using streamlined processes, extensive global buying power, a vast depot network and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s Turn-Key Operations (A-TKO™) model embraces the complexities and globalization of the clinical and ancillary supply chain by reducing both the overall cost and cycle time of clinical trials, and greatly improving operational efficiency across all levels of the value chain.

Ancillare has supported more than 1,500 clinical trials across 80,000 clinical sites over 100 countries with master depots in United States, United Kingdom, and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan, and Ukraine. To learn more, visit ancillare.com.

HORSHAM, PA. — Global Clinical and Ancillary Supply Chain leader Ancillare, LP—the only organization exclusively serving the end-to-end clinical and ancillary supply chain management needs of large- and middle-market pharmaceutical, biotechnology, and medical device companies, as well as contract and medical research organizations—today announced that David J. DelCollo, Esq., its primary in-house counsel, has been awarded both “Top 100 Lawyer” and “Top 40 Under 40” recognitions.

The recognitions come on the heels of DelCollo’s first year as Ancillare’s general counsel. Prior to joining Ancillare, he served as Senior Counsel for Bioclinica, where he worked to develop and protect the company’s intellectual property and licensing rights. DelCollo brought more than a decade of legal experience in practice areas such as corporate, contract and healthcare law to Ancillare—knowledge which he made quick use of, according to Ancillare leadership.

“David has made tremendous contributions this year and I think these awards are apropos,” said Joanne Santomauro, CEO at Ancillare. “He’s a skilled attorney. Not only as he helped [Ancillare] define our legal policies, he’s put us on a path to a more secure future.”

Prior to his success in corporate law, DelCollo represented the Commonwealth in the courtroom. As an Assistant District Attorney in the Greater Philadelphia Area, he personally prosecuted over 1,000 cases, winning favorable verdicts and outcomes 97% of the time.

DelCollo holds a J.D. from Widener University School of Law, where he was a member of the Trial Advocacy team.

The recognition of “Top 100 Lawyer” was awarded by executive profile publication International Top 100 Magazine. DelCollo’s “Top 40 Under 40” spotlight will be featured a forthcoming 2018 edition of the same magazine.

About Ancillare, LP

Ancillare is the only organization of its kind with a singular focus on the global clinical and ancillary supply chain. Ancillare arms sponsors of global clinical trials with a customized, end-to-end Ancillare Supply Plan, enabling developers of new therapies to optimize their clinical study supply chains using streamlined processes, extensive global buying power, a vast depot network and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s A-TKO™ model embraces the complexities and globalization of the clinical and ancillary supply chain by reducing both the overall cost and cycle time of clinical trials, and greatly improves operational efficiency across all levels of the value chain.

Ancillare has experience in working over 100 countries with master depots in United States, United Kingdom, and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan, and Ukraine.